CRISPR Therapeutics AG Insider Trading Activity
Every SEC Form 4 insider transaction reported for CRISPR Therapeutics AG (CRSP), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are CRSP insiders buying or selling?
In the last 12 months, CRISPR Therapeutics AG insiders reported 1 open-market purchase ($49.7K) and 23 sales ($19.0M) — net selling of $19.0M. Since January 2018, Trabud has recorded 158 Form 4 filings for CRSP: 8 buys ($69.7M) and 150 sells ($388.6M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $49.7K by Naimish Patel (Chief Medical Officer) on Jan 27, 2026. SEC ↗
- The most recent open-market purchase was reported on Jan 27, 2026 (8 months ago).
Key Statistics (January 2018 – Oct 16, 2026)
Total Form 4 filings
158
SEC EDGAR
Insider filers
22
Insider buys (8)
$69.7M
Insider sells (150)
$388.6M
Insider sentiment
Net sellingNet insider flow of $319.0M in net selling since January 2018, and $19.0M in net selling over the last 12 months.
Recent CRSP insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Simeon George | Director | Sale | 14.5K | $49.63 | $720.4K | SEC ↗ |
| Oct 15, 2026 | James R. Kasinger | General Counsel and Secretary | Sale | 1.0K | $49.26 | $51.2K | SEC ↗ |
| Oct 15, 2026 | Samarth Kulkarni | Chief Executive Officer | Sale | 4.1K | $49.26 | $201.9K | SEC ↗ |
| Oct 8, 2026 | James R. Kasinger | General Counsel and Secretary | Sale | 2.0K | $60.04 | $119.5K | SEC ↗ |
| Sep 24, 2026 | James R. Kasinger | General Counsel and Secretary | Sale | 10.4K | $60.24 | $626.5K | SEC ↗ |
| Sep 21, 2026 | Ali Behbahani | Director | Sale | 13.7K | $57.09 | $780.9K | SEC ↗ |
| Jun 1, 2026 | Naimish Patel | Chief Medical Officer | Sale | 3.8K | $55.62 | $210.6K | SEC ↗ |
| Mar 24, 2026 | James R. Kasinger | General Counsel and Secretary | Sale | 3.2K | $46.78 | $148.9K | SEC ↗ |
| Mar 24, 2026 | Samarth Kulkarni | Chief Executive Officer | Sale | 10.0K | $46.78 | $468.7K | SEC ↗ |
| Mar 24, 2026 | Raju Prasad | Chief Financial Officer | Sale | 3.7K | $46.78 | $173.5K | SEC ↗ |
| Mar 17, 2026 | Naimish Patel | Chief Medical Officer | Sale | 3.1K | $48.26 | $152.0K | SEC ↗ |
| Mar 17, 2026 | Raju Prasad | Chief Financial Officer | Sale | 9.9K | $48.26 | $476.3K | SEC ↗ |
| Mar 17, 2026 | James R. Kasinger | General Counsel and Secretary | Sale | 3.5K | $48.26 | $166.5K | SEC ↗ |
| Mar 17, 2026 | Samarth Kulkarni | Chief Executive Officer | Sale | 10.3K | $48.26 | $499.4K | SEC ↗ |
| Mar 12, 2026 | James R. Kasinger | General Counsel and Secretary | Sale | 2.8K | $52.80 | $147.8K | SEC ↗ |
| Mar 12, 2026 | Samarth Kulkarni | Chief Executive Officer | Sale | 9.8K | $52.80 | $517.3K | SEC ↗ |
| Feb 20, 2026 | Samarth Kulkarni | Chief Executive Officer | Sale | 7.0K | $52.58 | $366.3K | SEC ↗ |
| Feb 20, 2026 | James R. Kasinger | General Counsel and Secretary | Sale | 2.1K | $52.58 | $111.0K | SEC ↗ |
| Jan 27, 2026 | Naimish Patel | Chief Medical Officer | Purchase | 1.5K | $32.96 | $49.7K | SEC ↗ |
| Jan 26, 2026 | Raju Prasad | Chief Financial Officer | Sale | 35.0K | $60.19 | $2.1M | SEC ↗ |
| Jan 22, 2026 | Samarth Kulkarni | Chief Executive Officer | Sale | 90.0K | $57.40 | $5.2M | SEC ↗ |
| Jan 8, 2026 | Raju Prasad | Chief Financial Officer | Sale | 29.7K | $60.16 | $1.8M | SEC ↗ |
| Dec 23, 2025 | Raju Prasad | Chief Financial Officer | Sale | 10.0K | $55.95 | $559.5K | SEC ↗ |
| Oct 20, 2025 | Samarth Kulkarni | Chief Executive Officer | Sale | 50.9K | $67.91 | $3.5M | SEC ↗ |
| Oct 15, 2025 | Samarth Kulkarni | Chief Executive Officer | Sale | 4.2K | $66.60 | $282.5K | SEC ↗ |
Showing the 25 most recent of 158 Form 4 filings for CRISPR Therapeutics AG.
Most active CRSP insiders
- Samarth Kulkarni44 filings
- Phd J Bolzon Bradley25 filings
- Rodger Novak18 filings
- James R. Kasinger15 filings
- Raju Prasad8 filings
Ask anything about CRSP insider activity
Use Trabud's AI agent to query CRISPR Therapeutics AG's Form 4 history in plain English — "Show me CRSP CEO purchases this year" or compare it against any other ticker.
Open the AI agentCRSP insider trading FAQ
Are CRISPR Therapeutics AG insiders buying or selling?
In the last 12 months, CRISPR Therapeutics AG insiders reported 1 open-market purchase ($49.7K) and 23 sales ($19.0M) — net selling of $19.0M. Since January 2018, Trabud has recorded 158 Form 4 filings for CRSP: 8 buys ($69.7M) and 150 sells ($388.6M). Over the full record that is net selling of $319.0M.
How many insiders trade CRSP stock?
22 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for CRISPR Therapeutics AG. The most recent filing was accepted on Oct 16, 2026.
Where does Trabud get CRSP insider trading data?
All CRSP insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.